Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis
- PMID: 32699404
- PMCID: PMC7376149
- DOI: 10.1038/s41598-020-68848-9
Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis
Abstract
We employed Mendelian randomization (MR) to evaluate the causal relationship between leukocyte telomere length (LTL) and amyotrophic lateral sclerosis (ALS) with summary statistics from genome-wide association studies (n = ~ 38,000 for LTL and ~ 81,000 for ALS in the European population; n = ~ 23,000 for LTL and ~ 4,100 for ALS in the Asian population). We further evaluated mediation roles of lipids in the pathway from LTL to ALS. The odds ratio per standard deviation decrease of LTL on ALS was 1.10 (95% CI 0.93-1.31, p = 0.274) in the European population and 0.75 (95% CI 0.53-1.07, p = 0.116) in the Asian population. This null association was also detected between LTL and frontotemporal dementia in the European population. However, we found that an indirect effect of LTL on ALS might be mediated by low density lipoprotein (LDL) or total cholesterol (TC) in the European population. These results were robust against extensive sensitivity analyses. Overall, our MR study did not support the direct causal association between LTL and the ALS risk in neither population, but provided suggestive evidence for the mediation role of LDL or TC on the influence of LTL and ALS in the European population.
Conflict of interest statement
The authors declare no competing interests.
Figures


References
-
- Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617–628. - PubMed
-
- Armon C. Smoking is a cause of amyotrophic lateral sclerosis. High low-density lipoprotein cholesterol levels? Unsure. Ann. Neurol. 2019;85:465–469. - PubMed
-
- Zhan Y, Fang F. Smoking and amyotrophic lateral sclerosis: a mendelian randomization study. Ann. Neurol. 2019;85:482–484. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MR/L501542/1/MRC_/Medical Research Council/United Kingdom
- G-0907/PUK_/Parkinson's UK/United Kingdom
- MC_U123160651/MRC_/Medical Research Council/United Kingdom
- G0701075/MRC_/Medical Research Council/United Kingdom
- MC_UU_00024/1/MRC_/Medical Research Council/United Kingdom
- G0900652/MRC_/Medical Research Council/United Kingdom
- P30 AG062422/AG/NIA NIH HHS/United States
- G0301152/MRC_/Medical Research Council/United Kingdom
- G0400074/MRC_/Medical Research Council/United Kingdom
- R01 MH120794/MH/NIMH NIH HHS/United States
- R01 AG062268/AG/NIA NIH HHS/United States
- MR/N026004/1/MRC_/Medical Research Council/United Kingdom
- G0901254/MRC_/Medical Research Council/United Kingdom
- P30 AG066462/AG/NIA NIH HHS/United States
- G0502157/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical